aztreonam has been researched along with Disease, Pulmonary in 6 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A noncomparative pilot study was conducted to assess the potential usefulness of aztreonam in pulmonary exacerbations of cystic fibrosis." | 7.67 | Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| "A noncomparative pilot study was conducted to assess the potential usefulness of aztreonam in pulmonary exacerbations of cystic fibrosis." | 3.67 | Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | 1.35 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) |
| " Moreover, in 14 subjects affected by pulmonary interstitial diseases who underwent diagnostic broncho-alveolar lavage, we dosed AZT in lavage fluids about 1 hour after the injection of a 2 g dose (Group C: 8 cases) or a 4 g dose (Group D: 6 cases)." | 1.28 | Aztreonam activity in pneumology. Part 1: Clinical activity and pulmonary bioavailability of two different administration regimens. ( Bonucchi, ME; Calzati, A; Capelli, O; Covi, M; Gilioli, F; Lega, M; Rovatti, E; Velluti, G, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Máiz, L | 1 |
| Girón, RM | 1 |
| Olveira, C | 1 |
| Quintana, E | 1 |
| Lamas, A | 1 |
| Pastor, D | 1 |
| Cantón, R | 1 |
| Mensa, J | 1 |
| Sabet, M | 1 |
| Miller, CE | 1 |
| Nolan, TG | 1 |
| Senekeo-Effenberger, K | 1 |
| Dudley, MN | 1 |
| Griffith, DC | 1 |
| Ernst, EJ | 1 |
| Hashimoto, S | 1 |
| Guglielmo, J | 1 |
| Sawa, T | 1 |
| Pittet, JF | 1 |
| Kropp, H | 1 |
| Jackson, JJ | 1 |
| Wiener-Kronish, JP | 1 |
| Velluti, G | 1 |
| Capelli, O | 1 |
| Bonucchi, ME | 1 |
| Calzati, A | 1 |
| Lega, M | 1 |
| Rovatti, E | 1 |
| Gilioli, F | 1 |
| Covi, M | 1 |
| Aquino, G | 1 |
| Barbera, S | 1 |
| Romano, F | 1 |
| Zottola, V | 1 |
| Bosso, JA | 1 |
| Black, PG | 1 |
| Matsen, JM | 1 |
1 review available for aztreonam and Disease, Pulmonary
| Article | Year |
|---|---|
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Colistin; Cystic Fibr | 2013 |
5 other studies available for aztreonam and Disease, Pulmonary
| Article | Year |
|---|---|
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani | 2009 |
Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.
Topics: Animals; Aztreonam; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug | 1999 |
Aztreonam activity in pneumology. Part 1: Clinical activity and pulmonary bioavailability of two different administration regimens.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Biological Availability; Bronchoalveolar Lavage Fluid; Dr | 1991 |
[Use of aztreonam in the treatment of acute and flare-ups of chronic infectious bronchopneumopathies].
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Bronchial Diseases; Bronchopneumoni | 1988 |
Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Aztreonam; Bacterial Infections; Child; Cystic Fibrosis; Female; Humans; Lung Dis | 1987 |